New Hope for Heart Failure Patients.
Introducing a less invasive heart failure treatment from BioVentrix.
The Revivent™ Myocardial Anchoring System ranks among the most important recent innovations in heart failure (HF) therapy. This novel technology facilitates Less Invasive Ventricular Enhancement™ (LIVE™), an advancement that addresses the growing, global need for an effective but less invasive HF treatment for patients with the most prevalent cause of heart failure, who now are largely untreated.
Heart failure is a syndrome characterized by inadequate cardiac function. It results from multiple causes, including valve problems, high blood pressure, infection or simply dilation and dysfunction. Where possible, physicians tailor treatment to address the root cause—for example, replacing or repairing a faulty valve or treating high blood pressure.
The most prevalent kind of HF is caused by ischemic cardiomyopathy. This condition results from a previous heart attack that has damaged the left ventricle (LV), the portion of the heart muscle responsible for pumping blood to the rest of the body. This damage renders the heart misshapen, scarred and unable to pump blood at the proper strength or volume. A specific, widely applicable treatment for ischemic cardiomyopathy has never been available before.
The Revivent™ Myocardial Anchoring System restores size, volume and pumping efficiency.
Other technologies have attempted to address the disabling effects of congestive heart failure (CHF) with patches and pumps. But none of these approaches correct the underlying problem: compromised left ventricle size and function. That is, until now.
The Revivent System gives physicians an alternative that not only leads to better patient outcomes and quality of life, but does so with lower risk than any standard LV reconstruction surgery previously available. In so doing, LIVE therapy restores hope for suffering heart failure patients, and for their caregivers and families.
The Revivent™ Myocardial Anchoring System is under clinical investigation and is not yet commercially available.